Trial Profile
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2018
Price :
$35
*
At a glance
- Drugs Nirsevimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 25 Jan 2018 Results published in the Pediatric Infectious Disease Journal
- 08 Oct 2017 Results presented at the IDWeek 2017
- 14 Nov 2016 Status changed from active, no longer recruiting to completed.